Pfizer's (PFE) Cibinqo Approved in EU for Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. DPZ
6. PRIM
7. META
8. SPY
9. MTB
10. NAVN

Go back to Pfizer's (PFE) Cibinqo Approved in EU for Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

December 10, 2021 9:27 AM EST

Cibinqo is a once-daily oral treatment with proven efficacy demonstrated in a large-scale clinical trial program

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic... More